International audienceMultiple myeloma (MM) and its precursor condition MGUS are characterized by chromosomal aberrations. Here, we comprehensively characterize the order of occurrence of these complex genomic events underlying MM development using 500 MGUS, and MM samples. We identify hyperdiploid MM (HMM) and non-HMM as genomically distinct entities with different evolution of the copy number alterations. In HMM, gains of 9,15 or 19 are the first and clonal events observed as clonal even at MGUS stage. These events are thus early and may underlie initial transformation of normal plasma cells to MGUS cells. However, CNAs may not be adequate for progression to MM except in 15% of the patients in whom the complex subclonal deletion events ar...
Plasma cell dyscrasias are a heterogeneous group of diseases characterized by the expansion of bone ...
Multiple myeloma (MM) is a treatable, but incurable, malignancy of plasma cells (PC) in the bone mar...
Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical feature...
International audienceMultiple myeloma (MM) and its precursor condition MGUS are characterized by ch...
Symptomatic multiple myeloma (MM) is preceded by an indolent expansion of clonal plasma cells, known...
Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the clonal prolife...
These authors contributed equally : Francesco Maura and Niccoló Bolli. These authors jointly supervi...
none18siThe mechanisms involved in the progression from monoclonal gammopathy of undetermined signif...
Genetic events mediating transformation from premalignant monoclonal gammopathies (MG) to multiple m...
Multiple myeloma (MM) is a malignancy of clonal plasma cells (PC) which develops as a consequence of...
International audienceMultiple myeloma (MM) is characterized by wide variability in the chromosomal/...
On the basis of hyperdiploidy, often involving trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 2...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multi...
Plasma cell dyscrasias are a heterogeneous group of diseases characterized by the expansion of bone ...
Multiple myeloma (MM) is a treatable, but incurable, malignancy of plasma cells (PC) in the bone mar...
Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical feature...
International audienceMultiple myeloma (MM) and its precursor condition MGUS are characterized by ch...
Symptomatic multiple myeloma (MM) is preceded by an indolent expansion of clonal plasma cells, known...
Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the clonal prolife...
These authors contributed equally : Francesco Maura and Niccoló Bolli. These authors jointly supervi...
none18siThe mechanisms involved in the progression from monoclonal gammopathy of undetermined signif...
Genetic events mediating transformation from premalignant monoclonal gammopathies (MG) to multiple m...
Multiple myeloma (MM) is a malignancy of clonal plasma cells (PC) which develops as a consequence of...
International audienceMultiple myeloma (MM) is characterized by wide variability in the chromosomal/...
On the basis of hyperdiploidy, often involving trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 2...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multi...
Plasma cell dyscrasias are a heterogeneous group of diseases characterized by the expansion of bone ...
Multiple myeloma (MM) is a treatable, but incurable, malignancy of plasma cells (PC) in the bone mar...
Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical feature...